T-cell prolymphocytic leukemia

References

• Galton DAG, Goldman JM, Wiltshaw E et al. Prolymphocytic leukaemia. Br. J. Haematol.27, 7–23 (1974).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Galetto J, Okas A et al. Prolymphocytic leukemia of B and T cell type. Lancet2, 232–234 (1973).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL et al.WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (4th Edition). International Agency for Research on Cancer, Lyon, France (2008).
   Google Scholar
• Bommhardt U, Beyer M, Hunig T, Reichardt HM. Molecular and cellular mechanisms of T cell development. Cell. Mol. Life Sci.61, 263–280 (2004).
   PubMed Web of Science ®Google Scholar
• Pawson R, Schulz TF, Matutes E et al. The human T-cell lymphotropic viruses type 1/11 are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukaemia11, 1305–1311 (1997).
   PubMed Web of Science ®Google Scholar
• Virgilio L, Narducci MG, Isobe M et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc. Natl Acad. Sci. USA91, 12530–12534 (1994).
   PubMed Web of Science ®Google Scholar
• Lan K, Murakami M, Choudhuri T et al. Detection of Epstein–Barr virus in T-cell prolymphocytic leukemia cells in vitro.J. Clin. Virol.43(3), 260–265 (2008).
   PubMed Web of Science ®Google Scholar
• Herling M, Patek KA, Teitell MA et al. High TCL1 expression and intact T-cell receptor signalling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood111, 328–337 (2008).
   PubMed Web of Science ®Google Scholar
• Madani A, Choukroun V, Soulier J et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood87, 1923–1927 (1996).
   PubMedGoogle Scholar
• Laine J, Kunstle G, Obata T et al. The proto-oncogene TCL1 is an Akt kinase coactivator. Mol. Cell6, 395–407 (2000).
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet. Cytogenet.55, 1–9 (1991).
   PubMed Web of Science ®Google Scholar
• Xu Y, Ashley T, Brainerd E et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects and thymic lymphoma. Genes Dev.10, 2411–2422 (1996).
   PubMed Web of Science ®Google Scholar
• Taylor AM, Metcalfe JA, Thick M et al. Leukaemia and lymphoma in ataxia telangiectasia. Blood87, 423–438 (1996).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schaffner C, Litterst A et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med.3, 1155–1159 (1997).
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D, Soulier J, Lauge A et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood91, 3920–3926 (1998).
   PubMed Web of Science ®Google Scholar
• Yuille MA, Coignet LJ. The ataxia telangiectasia gene in familial and sporadic cancer. Recent Results Cancer Res.154, 156–173 (1998).
   PubMedGoogle Scholar
• Yamaguchi M, Yamamoto K, Miki T et al. T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. Cancer Genet. Cytogenet.146, 22–26 (2003).
   PubMedGoogle Scholar
• Matutes E, Brito-Babapulle V, Swansbury J et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood78, 3269–3274 (1991).
   PubMed Web of Science ®Google Scholar
• Garand R, Goasguen J, Brizard A et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d’Haematologie Cellularie. Br. J. Haematol.103, 488–494 (1998).
   PubMed Web of Science ®Google Scholar
• Matutes E, Talavera GJ, O’Brien M et al. The morphological spectrum of T-prolymphocytic leukemia. Br. J. Haematol.64, 111–124 (1986).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22, 185–191 (1998).
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Imoto S, Matsuo Y et al. T-cell receptor γ-δ T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann. Hematol.80, 749–751 (2001).
   PubMed Web of Science ®Google Scholar
• Malajei SH, Brito-Babapulle V, Hirons LR et al. Abnormalities of chromosomes 8, 11, 14 and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet. Cytogenet.103, 110–116 (1998).
   PubMedGoogle Scholar
• Kojima K, Kobayashi H, Imoto S et al. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. Int. J. Hematol.68, 291–296 (1998).
   PubMed Web of Science ®Google Scholar
• Soulier J, Pierron G, Vecchione D et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer31, 248–254 (2001).
   PubMed Web of Science ®Google Scholar
• Durig J, Bug S, Klein-Hitpass L et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukaemia with inv (14)(q11q32). Leukaemia21(10), 2153–2163 (2007).
   PubMed Web of Science ®Google Scholar
• Delgado J, Bustos JG, Jimenez MC et al. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders? Leuk. Lymphoma43, 2331–2334 (2002).
   PubMed Web of Science ®Google Scholar
• Mercieca J, Matutes E, Dearden C et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol.12, 2588–2593 (1994).
   PubMed Web of Science ®Google Scholar
• Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol.15, 2667–2672 (1997).
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood98, 1721–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol.20, 205–213 (2002).
   PubMed Web of Science ®Google Scholar
• Dearden C, Matutes E, Cazin B et al. Very high response rates in previously untreated T-cell prolymphocytic leukemia patients receiving alemtuzumab (Campath-1H) therapy. Blood102 (2003) (Abstract 2378).
   PubMedGoogle Scholar
• Khot A, Matutes E, Dearden C et al. Alemtuzumab administered by subcutaneous route is less effective than intravenous route for first line therapy of T-cell prolymphocytic leukaemia: results of a pilot study (UKCLL05). Blood (ASH Annual Meeting Abstracts)112 (2008) (Abstract 4204).
   Google Scholar
• Hopfinger G, Kandler G, Koller E et al. T-PLL 1 protocol of the German CLL Study Group (GCLLSG) – a prospective Phase 2 trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FCM) followed by alemtuzumab consolidation as first line treatment in T-PLL. Blood (ASH Annual Meeting Abstracts), 110 (2007) (Abstract 2130).
   Google Scholar
• Ravandi-Kashani F, Kantarjian H, Faderl S et al. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Blood (ASH Annual Meeting Abstracts) (2006) (Abstract 4971).
   Google Scholar
• Krishnan B, Cazin B, Ireland R et al. Improved survival for patients with T-cell prolymphocytic leuk receiving alemtuzumab therapy followed by stem cell transplantation. Leuk. Lymphoma48(Suppl. 1), 6–13 (2007).
   Google Scholar
• Garderet L, Bittencourt H, Kaliski A et al. Treatment of T-prolymphocytic leukaemia with non-myeloablative allogeneic stem cell transplantation. Eur. J. Haematol.66, 137–139 (2001).
   PubMed Web of Science ®Google Scholar
• De Lavallade H, Faucher C Furst S et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukaemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplant.37, 709–710 (2006).
   PubMedGoogle Scholar
• Ozpuyan F, Meyer P, Ni H, Al-Masri H, Alkan S. Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL). Leuk. Lymphoma48(11), 2247–2250 (2007).
   PubMed Web of Science ®Google Scholar
• Satou Y, Matsuoka M. Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells. Nippon Rinsho62(7), 1363–1367 (2004).
   PubMedGoogle Scholar
• Roeth A, de Beer D, Duerig J et al. Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): an optimal target for telomerase inhibition with GRN163L? J. Clin. Oncol.26(Suppl.) (2007) (Abstract 7061).
   Google Scholar
• Ishitsuka K, Yotsumoto F, Katsuya H et al. A promising therapeutic implication of a novel Bcl-2 family inhibitor ABT-737 for adult T-cell leukemia/lymphoma. Blood (ASH Annual Meeting Abstracts)112 (2008) (Abstract 1584).
   Google Scholar
• Yamamoto K, Tobinai K, Utsunomiya A et al. Phase I study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL): updated results. Blood (ASH Annual Meeting Abstracts)112 (2008) (Abstract 1007).
   Google Scholar
• Maeda Y, Yamaguchi T, Hirase C et al. Clinical efficacy of ATRA for adult T-cell leukemia. Blood (ASH Annual Meeting Abstracts), 112 (2008) (Abstract 4985).
   Google Scholar
• Horwitz S, Duvic M, Kim Y et al. Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose-finding trial. Blood (ASH Annual Meeting Abstracts), 112 (2008) (Abstract 1569).
   Google Scholar
• Zhao Y, Xu Y, Lan J et al. Anti-proliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Blood (ASH Annual Meeting Abstracts), 110 (2007) (Abstract 4285).
   Google Scholar